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Abstract
Gene fusions involving the erythroblast transformation-specific (ETS) transcription factors ERG, ETV1, ETV4, ETV5, and FLI1
are a common feature of prostate carcinomas (PCas). Themost common upstream fusion partner described is the androgen-
regulated prostate-specific gene TMPRSS2, most frequently with ERG, but additional 5′ fusion partners have been described.
We performed 5′ rapid amplification of cDNA ends in 18 PCas with ETV1, ETV4, or ETV5 outlier expression to identify the
5′ fusion partners. We also evaluated the exon-level expression profile of these ETS genes in 14 cases. We identified and
confirmed by fluorescent in situ hybridization (FISH) and reverse transcription-polymerase chain reaction the two novel chi-
meric genesOR51E2-ETV1 andUBTF-ETV4 in twoPCas.OR51E2encodes aG-protein–coupled receptor that is overexpressed
in PCas, whereas UBTF is a ubiquitously expressed gene encoding an HMG-box DNA-binding protein involved in ribosome
biogenesis. We additionally describe two novel gene fusion combinations of previously described genes, namely, SLC45A3-
ETV4 andHERVK17-ETV4. Finally, we found one PCawith TMPRSS2-ETV1, onewithC15orf21-ETV1, onewithEST14-ETV1, and
two with 14q133-q21.1–ETV1. In nine PCas (eight ETV1 and one ETV5), exhibiting ETS outlier expression and genomic
rearrangement detected by FISH, no 5′ fusion partner was found. Our findings contribute significantly to characterize the
heterogeneous group of ETS gene fusions and indicate that all genes described as 5′ fusion partners with one ETS gene can
most likely be rearranged with any of the other ETS genes involved in prostate carcinogenesis.
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Introduction
Gene fusions involving the erythroblast transformation-specific (ETS)
transcription factor family of genes are a recurrent feature of prostate
adenocarcinomas (PCas). These gene aberrations, caused by chromo-
somal structural abnormalities, originate fusion transcripts that lead
to overexpression of N-truncated ETS proteins or, more rarely, to
full-length ETS proteins or chimeric fusion proteins [1–3]. Fusion
of the androgen-regulated promoter region of theTMPRSS2 gene with
ERG is the most common ETS rearrangement, being present in about
50% of PCa and in 20% of high-grade prostatic intraepithelial neo-
plasia lesions [1,4]. Other rarer fusion events can occur involving the
PEA3 subfamily of ETS members, namely, ETV1, ETV4, and ETV5
[1,5,6] or the ERG subfamily member FLI1 [3].
Besides the prostate-specific and androgen-induced TMPRSS2, sev-
eral ETS fusion partners have been described, namely, HERPUD1,
NDRG1, SLC45A3, ACSL3, HERV-K_22, HERVK17, CANT1,
DDX5, KLK2, FOXP1, EST14,HNRPA2B1, C15orf21, and the chro-
mosomal region 14q13.3-14q21.1 [2,7,8], presenting heterogeneous
tissue specificities and androgen responsiveness. Fusion partners like
the SLC45A3 gene or the endogenous retroviral element (HERVK17 )
display similar tissue specificity as TMPRSS2 and are equally androgen-
induced. Contrarily, the fusion partner C15orf21, despite being over-
expressed in PCas, is repressed by androgens. However, there are
ubiquitously expressed 5′ fusion partners, such as the HNRPA2B1
gene, displaying no evidence of androgen regulation. Finally, ETS fam-
ily genes may be rearranged with prostate-specific enhancers in chro-
mosomal regions such as 14q13.3-14q21.1.
We have previously performed a comprehensive characterization
of ETS rearrangements on a series of 200 clinically localized PCas
and found rearrangements involving ERG, ETV1, ETV4, ETV5,
and FLI1 in 52%, 7%, 1.5%, 0.5%, and 0.5%, respectively [3]. In
the present work, we focused on the 18 PCas that showed outlier
expression levels of ETV1, ETV4, or ETV5 and a genomic rearrange-
ment of the corresponding ETS locus. The combined use of exon-
level expression profiles from exon microarrays, 5′ rapid amplification
of cDNA ends (5′RACE), and fluorescence in situ hybridization (FISH)
with bacterial artificial chromosome (BAC)–specific probes allowed us
to identify novel 5′ fusion partners for ETV1 and ETV4, as well as to
describe novel combinations of genes known to be involved in PCa
gene fusions.
Materials and Methods
PCa Samples
We studied a set of 18 PCas with outlier mRNA expression levels
of ETV1 (n = 14), ETV4 (n = 3), and ETV5 (n = 1) and with a
genomic rearrangement previously demonstrated by FISH but with
yet unknown fusion partners [3]. These samples were selected from a
cohort of 200 patients with clinically localized PCa consecutively
diagnosed and treated with radical prostatectomy that were previously
typed for ETS rearrangements [3]. This study was approved by the
Institutional Review Board, and informed consent was obtained from
all subjects.
Gene Expression Microarrays
RNA was extracted from tissue samples using TRIzol (Invitrogen
by Life Technologies, Carlsbad, CA), as previously described [3], and
1 μg of RNA was processed into cDNA and hybridized to Affymetrix
GeneChip Human Exon 1.0 ST arrays, following the manufacturer’s
recommendations. The Affymetrix Expression Console v1.1 software was
used to obtain exon-level robust multi-array average (RMA)-normalized
expression values for the core probe sets only.
5′Rapid Amplification of cDNA Ends
The 5′RACE was performed using the SMARTer RACE cDNA
amplification kit and protocol (Clontech Laboratories, Inc, Saint-
Germain-en-Laye, France). Briefly, first-strand cDNA was reverse
transcribed from 1 μg of total RNA using the SMARTScribe Reverse
Transcriptase with the 5′RACE cDNA synthesis primer (5′-CDS)
and the SMARTer IIA oligo from the kit. An aliquot of the cDNA
was then amplified using a forward gene-specific primer (GSP) and a
universal primer mix. Polymerase chain reaction (PCR) conditions
used were as described by the manufacturer. Nested PCRs using
the nested universal primer as the reverse primer and a nested
gene-specific primer (NGSP) were performed to increase the specific-
ity and product yields of 5′RACE. Primers used on 5′RACE and
nested PCR are listed in Table W1. Nested PCR products were
analyzed on a 2% agarose gel (SeaKem LE Agarose; Lonza, Basel,
Switzerland) and the bands were purified using the QIAquick Gel
Extraction Kit (Qiagen, Hilden, Germany).
Cloning and Sequencing
Purified 5′ nested race PCR products were cloned into pCR4-
TOPO plasmids using the TOPO TA Cloning Kit for sequencing
(Invitrogen). Colonies were picked and the plasmids were purified
using the Qiagen Plasmid Miniprep Kit (Qiagen) and subsequently
sequenced using the M13 forward and T3 primers using BigDye
Terminator V3.1 sequencing chemistry on a 3730 DNA Analyzer
(Applied Biosystems by Life Technologies, Foster City, CA) accord-
ing to the manufacturer’s recommendations. Genomic alignment of
the resulting sequences was performed using BLAST (http://www.
ncbi.nlm.nih.gov/blast/) and BLAT (http://genome.ucsc.edu/). All
exons identified were numbered according to the longest matching
transcripts of the Ensembl database (http://www.ensembl.org/).
Reverse Transcription–PCR
The reverse transcription (RT)–PCR assay for detection of pros-
tate fusion transcripts was performed with the following primer
combinations: TMPRSS2_F and ETV1_R (TMPRSS2-ETV1),
C15orf21_S and ETV1_AS1 (C15orf21-ETV1), SLC45A3_S and
ETV4_AS (SLC45A3-ETV4), UBTF-S and ETV4_AS (UBTF-
ETV4), OR51E2_S and ETV1_AS2 (OR51E2-ETV1), EST14_S and
ETV1_AS2 (EST14-ETV1), and HERVK17_S and ETV4_AS
(HERVK17-ETV4; Table W2). PCRs were performed with the Qiagen
OneStep RT-PCR Kit (Qiagen) according to the manufacturer’s
instructions. Amplified products were analyzed on a 2% agarose gel
and further validated by sequencing.
Fluorescence In Situ Hybridization
To validate the 5′RACE findings, we performed FISH using BAC
clones targeting the 5′ fusion partner and the ETS gene on tissue sec-
tions from paraffin blocks of the index tumor (Table W3). BAC
clones were selected using the University of California, Santa Cruz
(UCSC) Human Genome Browser and obtained from the BACPAC
Resources Centre (Oakland, CA). BAC DNA was extracted, ampli-
fied, labeled, and prepared for hybridization as previously reported
[9]. Adequate mapping and probe specificity of all BAC clones was
confirmed by hybridization onto human metaphase spreads of normal
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lymphocytes. An abnormal signal pattern was considered representa-
tive when present in a minimum of 50 morphologically intact, non-
overlapping nuclei.
In Silico Analysis of Androgen Effect on Gene Expression
To study the effect of androgen stimulus on UBTF and OR51E2
expression, we used the expression data of the LNCaP cell line that
can be accessed from the Gene Expression Omnibus (GSE32875)
[10]. The normalized expression values of OR51E2 and UBTF in
four replicates of the LNCaP cell line treated with a synthetic androgen
(R1881) and four replicates of the LNCaP cell line with no androgen
stimulus were compared using the paired sample t test.
Results and Discussion
The starting point of this study was a subset of 18 PCas with evidence
of rearrangement of ETV1, ETV4, and ETV5 and unknown 5′ fusion
partner from a larger cohort previously typed for ETS rearrangements
[3]. Of these 18 cases, there was evidence for involvement of ETV1 in
14 cases, of ETV4 in 3 cases, and of ETV5 in 1 case, in every instance
presenting outlier expression and genomic rearrangement by FISH [3].
After analyzing the exon-level expression data of 51 PCas [11], includ-
ing 14 of the 18 cases included in this report, we here show that in
samples P262T, P274T, P451T, and P542T the exons of ETV1 are
differentially expressed between the 5′ and 3′ ends, pinpointing the
breakpoint before exons 4, 7, 8, and 7, respectively (Figure 1). Differ-
ences in the exon expression profile of ETV4 and ETV5 are present
in samples P522T and P261T, respectively, indicating breakpoints
before exon 5 of ETV4 and before exon 6 of ETV5 (Figure 1). In
the remaining cases, all exons of the rearranged ETS gene were simi-
larly overexpressed. To unveil the 5′ fusion partners involved in these
ETS gene fusions, we initially performed RT-PCR in all 18 PCas
with primers targeting themost commonly involved 5′ fusion partners,
namely, TMPRSS2 and SLC45A3. The TMPRSS2-ETV1 fusion tran-
script was detected in one of the 14 PCas with ETV1 rearrangement
(P500T), and the SLC45A3-ETV4 fusion transcript was found in one
of the three samples with ETV4 rearrangement (P236T; Figure W1).
Given our recent findings of occasional heterogeneity of PCa gene
fusions in different areas of the same tumor [3], all samples were fur-
ther investigated by 5′RACE PCR. Sequencing of the 5′RACE PCR
products of cases P451T and P522T unveiled OR51E2 and UBTF as
novel 5′ fusion partners of ETV1 and ETV4, respectively. The
OR51E2-ETV1 transcript was composed by the untranslated exon 1
of OR51E2 (ENST00000396950), with an additional untranslated
292-bp sequence downstream of exon 2 of OR51E2, fused to exon 8
of ETV1 (Figure 2), which includes an in-frame ATG start codon
(amino acid 132). As previously described [12,13], gene fusions in-
volving noncoding regions of the 5′ partner with exon 8 of ETV1
results in an N-truncated ETV1 protein with 345 amino acids. An
alternative transcript fusing exon 9 of ETV1 with the same OR51E2
sequences was also found, with the predicted resulting protein start-
ing at an internal ATG in exon 9 of ETV1 (amino acid 203) and
consisting of 274 amino acids. The presence of both OR51E2-
ETV1 fusion transcripts was confirmed by RT-PCR. The OR51E2
and ETV1 genes map to chromosome bands 11p15 and 7p21, re-
spectively, and have the same transcriptional orientation, which in-
dicates that this novel fusion gene was originated by a chromosomal
translocation. TheOR51E2 (alias PSGR) is named as olfactory receptor,
family 51, subfamily E, member 2, and encodes a member of a large
family of G-protein–coupled receptors arising from single coding exon
Figure 1. Exon-level expression profiles. RMA-normalized exon-
level expression profile of ETV1, ETV4, and ETV5 in 51 PCas obtained
using Affymetrix GeneChip Human Exon 1.0 ST arrays. Differential
expression of exons at the 5′ and 3′ ends of ETV1 (A) was found in
four samples (P262T, P275T, P451T, and P542T), indicating break-
point before exons 4, 7, 8, and 7, respectively, whereas samples
P522T and P261T displayed differential expression of exons at the
5′ and 3′ ends of ETV4 (B) and ETV5 (C), respectively, with a break-
point before exon 5 of ETV4 and exon 6 of ETV5. Gray lines represent
samples with normal ETS expression, whereas gray dashed lines
represent samples with overexpression of the whole transcript.
For all genes, exons are numbered according to the indicated
Ensembl transcript identifiers. The array included two probe sets tar-
geting proximal and distal regions of exon 7 of ETV1 and exon 8 of
ETV5 depicted in the plot as 7a and 7b and 8a and 8b, respectively.
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genes. It has been described by several authors to have a prostate-
specific expression pattern and has also been found overexpressed in
PCa [14] (Figure W2). The OR51E2-ETV1 fusion retains the tissue
specific regulatory activity present in exon 1 of OR51E2, one of the
two described OR51E2 promoters [15]. A recent study of the gene
expression profile of benign and malignant prostate tissues from three
radical prostatectomies and from three prostate biopsies of surgically
castrated patients showed higher OR51E2 expression in benign/cancer
tissues compared to castrated prostate tissues [16], suggesting androgen
regulation. However, it has been shown that the two described
OR51E2 promoters are regulated by interleukin-6 but not by the
synthetic androgen R1881 [15]. Furthermore, we performed in silico
analysis of public microarray data of R1881-treated LNCaP cells and
found no alteration ofOR51E2 expression after androgenic stimulation
(Figure 2; microarray data originally published in [10]).
The second novel fusion transcript UBTF-ETV4 is composed by
the untranslated exon 1 and exon 2 of UBTF (ENST00000393606)
fused to exon 5 of ETV4 (Figure 3). Sequencing also revealed a par-
tial deletion of exon 6 and exon 7 of ETV4 consisting in the loss of
29 and 148 bp, respectively. The presence of the UBTF-ETV4 fusion
transcript was confirmed by RT-PCR. Both genes are located in the
same chromosome band, 17q21, and are about 700 kb apart (Fig-
ure 3). Break apart probes flanking ETV4 showed deletion of the
probe targeting the 5′ ETV4 region, suggesting a cryptic deletion
in chromosome 17 between the two genes as the mechanism of
UBTF-ETV4 fusion. Exon 2 of UBTF contains the ATG start codon
and is in-frame with exon 5 of ETV4, so this gene fusion presumably
originates a chimeric protein containing 19 amino acids encoded by
exon 2 ofUBTF and anETV4 counterpart lacking the first 67N-terminal
amino acids as well as additional 59 amino acids resulting from the
partial deletion on exons 6 and 7 of ETV4. Interestingly, a previously
reported gene fusion in PCa involving exon 5 of ETV4 also translates
into a chimeric protein [17]. Although relatively rare, there is evidence
of other ETS fusion transcripts encoding chimeric proteins, namely,
Figure 2. Characterization of the gene fusion involvingOR51E2 and ETV1 in the clinical prostate cancer P451T with ETV1 outlier expression
and with an ETV1 genomic rearrangement previously demonstrated by FISH. (A) Fusion transcript of the untranslated exon 1 ofOR51E2 and
a downstream sequence of 292 bp of OR51E2 with exon 8 of ETV1 detected by sequencing of the 5′RACE PCR products using a reverse
primer on exon 10 of ETV1. The upper representation depicts wild-type transcripts of OR51E2 and ETV1, indicating its length and chromo-
somal localization. Exons are represented by boxes (colored if translated) and introns by horizontal lines. The scheme below represents the
wild-type cDNA, where untranslated regions are in lighter shades. (B) Interphase FISH on formalin-fixed, paraffin-embedded tissue of the
PCa P451T. Co-localization of probes for OR51E2 (red) and ETV1 (green) confirms genomic OR51E2-ETV1 fusion in the cancer cells. (C) RT-
PCR assay for detection ofOR51E2-ETV1 fusion transcript in the PCa P451T and in an ETS-negative PCa using a forward primer in the 292-bp
sequence downstream of OR51E2 and a reverse primer in exon 9 of ETV1. (D) Expression of OR51E2 is relatively unchanged in LNCaP cell
lines treated with an androgen analog (R1881) versus cells grown in dextran-coated charcoal culture medium as a control. The expression
data were obtained from the Gene Expression Omnibus (GSE32875).
Neoplasia Vol. 15, No. 7, 2013 Novel ETV1 and ETV4 Fusions in Prostate Cancer Barros-Silva et al. 723
TMPRSS2 fused with ERG, ETV1, ETV4, and ETV5, and the fusion
transcripts FOXP1-ETV1, EST14-ETV1, HNRPA2B1-ETV1, and
DDX5-ETV4 [2]. The UBTF (upstream binding transcription factor,
RNA polymerase I) gene encodes a member of the HMG-box DNA-
binding protein family [18,19], which plays a critical role in ribosomal
RNA (rRNA) transcription as a key component of the preinitiation
complex, mediating the recruitment of RNA polymerase I to ribosomal
DNA promoter regions. Synthesis of rRNA by Pol I, which drives
ribosome biogenesis, is an important determinant of the cellular growth
response [20]. This gene is ubiquitously expressed in different tissues
and does not display an increased expression in PCa (Figure W2).
Moreover, we here show by in silico analysis of public microarray data
that the expression of UBTF is not altered by androgen stimulus in the
LNCaP cell line (Figure 3; microarray data originally published in
[10]). Interestingly, it has been shown that the oncoprotein MYC
directly influences Pol I transcription of rRNA genes [20] and that it
positively regulates UBTF expression [21].
Besides UBTF, we here describe two additional novel ETV4 fusion
partners by 5′RACE PCR (Table 1). In sample P352T, we found a
fusion transcript of the prostate-specific androgen-repressed endoge-
nous retroviral element, HERVK17, fused to exon 5 of ETV4 (Fig-
ures 4 and W1). HERVK17 has previously been described as a fusion
partner for ETV1 [13]. Confirming the earlier findings by RT-PCR,
sequencing of the 5′RACE PCR product of sample P236T showed
an SLC45A3-ETV4 fusion transcript, in which exon 1 of SLC45A3
(ENST00000367145) is fused in-frame with exon 3 of ETV4 (Fig-
ures 4 and W1). ETV4 rearrangements involving exon 3 have been
previously described [5]. Interestingly, this tumor also harbors an
SLC45A3-ERG fusion in a different area of the same cancerous focus
[3], evidencing intratumor genetic heterogeneity in the form of two
different ETS genes fused with the same 5′ fusion partner, which
most likely resulted from collision of initially separated neoplasms/
foci. With the findings we here report, SLC45A3 has now been
found fused with all five ETS members known to be involved in
Figure 3. Characterization of the gene fusion involving UBTF and ETV4 in the clinical prostate cancer P522T with ETV4 outlier expression
and with an ETV4 genomic rearrangement previously demonstrated by FISH. (A) Fusion transcript of the untranslated exon 1 and exon 2
of UBTF with exon 5 of ETV4 detected by sequencing of the 5′RACE PCR products using a reverse primer on exon 10 of ETV4. The upper
representation depicts wild-type transcripts of UBTF and ETV4 indicating their length and chromosomal localization. Exons are rep-
resented by boxes (colored if translated) and introns by horizontal lines. The scheme below represents the wild-type cDNA, where
untranslated regions are in lighter shades. (B) Interphase FISH on formalin-fixed, paraffin-embedded tissue of the PCa P522T. Deletion
of the probe spanning the chromosome region between UBTF and ETV4 (red) indicates a cryptic deletion at chromosome 17 as the
genomic mechanism for UBTF-ETV4 gene fusion. (C) RT-PCR assay for detection of UBTF-ETV4 fusion transcript in the PCa P522T
and in an ETS-negative PCa using a forward primer in exon 2 of UBTF and a reverse primer in exon 6 of ETV4. (D) Expression of UBTF
is relatively unchanged in LNCaP cell lines treated with an androgen analog (R1881) versus cells grown in dextran-coated charcoal
culture medium as a control. The expression data were obtained from the Gene Expression Omnibus (GSE32875).
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prostate carcinogenesis, whereas TMPRSS2 has been described as 5′
fusion partner with four of these (all except FLI1).
Finally, sequencing of the 5′RACE PCR fragments showed gene
fusions that have previously been described in two additional cases.
Sample P274T showed the fusion of EST14 with exon 7 of ETV1, as
previously described by Hermans and co-workers [13], whereas in
sample P525T we found that the untranslated exon 1 of C15orf21
(ENST00000409454) is fused with exon 3 of ETV1, thus giving rise
to a full-length ETV1 protein (Figures 4 and W1). The latter is dif-
ferent from the previously described C15orf21-ETV1 fusion [22],
where exon 2 of C15orf21 was fused with exon 8 of ETV1. There
is evidence in the literature of fusion transcripts involving ETS genes
that include all their coding exons. Helgeson and co-workers de-
scribed a prostate tumor with four fusion transcripts of TMPRSS2-
ETV5, each including all coding exons of ETV5 [6]. More recently,
Gasi and colleagues described a prostate tumor harboring EST14-
ETV1 fusion transcripts including all coding exons of ETV1 and
overexpressing full-length ETV1 [23].
Contrarily to case P236T, in which the initial RT-PCR finding of
the SLC45A3-ETV4 gene fusion was later confirmed by 5′RACE PCR,
in one PCa the TMPRSS2-ETV1 fusion transcript was detected by
RT-PCR but not by 5′RACE PCR, which may be due to technical
difficulties of the 5′RACE methodology. The 11 cases where no
5′ fusion partner was found using both RT-PCR and 5′RACE
included 10 samples with evidence of ETV1 rearrangement and 1
with evidence of ETV5 rearrangement. The exon-level expression
profile of the prostate tumor P261T displayed differential expres-
sion of ETV5 exons 6 to13 compared to exons 1 to 5 (Figure 1);
however, no 5′ fusion partner was found either by RT-PCR or
5′RACE. Moreover, this sample was tested using a FISH approach
with probes flanking ETV5 combined with two additional probes
targeting the 5′ region of the two known ETV5 fusion partners
(TMPRSS2 and SLC45A3), but no evidence of involvement of these
genes was found. Further FISH analysis lead to the identification of
two cases with 14q13.3-q21.1–ETV1 rearrangement. Regarding the
eight ETV1 cases where no 5′ fusion partner was found, exon-level
expression data were available in six cases, of which one displayed dif-
ferential exon-level expression and the remaining five showed over-
expression of full-length ETV1 transcripts. This is in agreement with
a recent study of Gasi et al. [23], where, of five prostate tumors with
overexpression of full-length ETV1 transcripts and genomic rearrange-
ment of ETV1 determined by FISH, only in one case the 5′RACE
was efficient in identifying a fusion transcript, which turned out to
be EST14-ETV1.
Recent studies have brought new insights on the mechanisms
underlying chromosomal rearrangements in human cancer. Reports
describing androgen receptor–driven chromatin looping [24] and
ligand-bound androgen receptor recruitment of enzymes capable
of inducing double-strand breaks [25] suggest that androgen recep-
tor may play an important role in gene fusion formation in PCa.
Table 1. Summary of the Experimental Findings in 18 Prostate Tumors with ETV1, ETV4, or ETV5 Rearrangements.
Sample TLDA
Outlier
Expression
FISH Exon
Array
RT-PCR
(TMPRSS2/
SLC45A3-ETV1)
RT-PCR
(TMPRSS2/
SLC45A3-ETV4)
RT-PCR
(TMPRSS2/
SLC45A3-ETV5)
FISH
(14q13.3-q21.1–ETV1)
5′RACE
P262T ETV1 ETV1+ D neg. – – 14q13.3-q21.1–ETV1 neg.
P272T ETV1 ETV1+ W neg. – – neg. neg.
P305T ETV1 ETV1+ W neg. – – neg. neg.
P344T ETV1 ETV1+ W neg. – – n. a. neg.
P456T ETV1 ETV1+ W neg. – – 14q13.3-q21.1–ETV1 neg.
P488T ETV1 ETV1+ W neg. – – neg. neg.
P499T ETV1 ETV1+ W neg. – – neg. neg.
P525T ETV1 ETV1+ W neg. – – – C15orf 21-ETV1
P542T ETV1 ETV1+ D neg. – – neg. neg.
P274T ETV1 ETV1+ D neg. – – – EST14-ETV1
P451T ETV1 ETV1+ D neg. – – – OR51E2-ETV1
P271T ETV1 ETV1+ n. a. neg. – – neg. neg.
P498T ETV1 ETV1+ n. a. neg. – – neg. neg.
P500T ETV1 ETV1+ n. a. TMPRSS2-ETV1 – – – neg.
P236T ETV4 ETV4+ D – SLC45A3-ETV4 – – SLC45A3-ETV4
P352T ETV4 ETV4+ n. a. – neg. – – HERVK17-ETV4
P522T ETV4 ETV4+ D – neg. – – UBTF-ETV4
P262T ETV5 ETV5+ D – – neg. – neg.
TLDA indicates TaqMan low-density array; W, whole gene overexpression; D, differential exon expression; neg., negative; n. a., not analyzable.
Figure 4. Schematic representation of gene fusions involving known
ETS 5′fusion partners detected in PCas using 5′RACE, including the
two novel ETV4 fusion partners. ETV1 exons are represented in blue
and ETV4 exons in green, and noncoding regions are in lighter
shades. From top to bottom: Exon 1 of SLC45A3 fused with exon 3
of ETV4 (prostate cancer P236T); transcript of the endogenous
retroviral element HERVK17 fused with exon 4 of ETV4 (prostate
cancer P352T); exon 1 of C15orf21 fused with exon 3 of ETV1 (pros-
tate cancer P525T); exon 1 of EST14 fusedwith exon 7 of ETV1 (pros-
tate cancer P274T); exon 1 of TMPRSS2 fused with exon 4 of ETV1
(prostate cancer P500T).
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Another critical aspect of chromosome rearrangements is the spatial
proximity of the partners involved. Growing evidence indicates that
the formation of tumor translocations is partially affected by higher
order genomic organization in nuclear territory [26]. In light of this,
future work may show that the new fusion partners here described
occupy the same nuclear domain.
In summary, this study contributes significantly to characterize the
pattern of fusion genes in PCa, as we report two novel 5′ fusion part-
ners (OR51E2-ETV1 and UBTF-ETV4) of ETS rearrangements, as
well as two novel gene fusion combinations involving previously de-
scribed genes (SLC45A3-ETV4 and HERVK17-ETV4). Our findings
suggests that not only may there be more 5′ partner genes yet to be
identified in PCa but also that all the genes described as 5′ fusion
partners with one ETS gene can most likely be rearranged with
any of the other ETS genes known to be involved in PCa.
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Table W1. Oligonucleotide Primer Sequences for 5′RACE PCR.
Primer Oligonucleotide Sequence (5′→3′) Ensembl Transcript Exon
ETV1_R_GSP GTTCTGCTGGGATGAGCCAGGAAGC ENST00000430479 10
ETV1_F_IC TCCCTCCATCGCAGTCCATACCAGA ENST00000430479 8
ETV1_R_NGSP AAGCCTTGTGGTGGGAAGGGGATGT ENST00000430479 9
ETV4_R_GSP CAGGGACAACGCAGACATCATCTGG ENST00000319349 10
ETV4_F_IC CATGGCGAGCAGTGCCTTTACTCCA ENST00000319349 6
ETV4_R_NGSP GGCGAAGTCCGTCTGTTCCTGTTTGA ENST00000319349 8
ETV5_R_GSP CTCTCAGGCACAACACAAGTGTCGTCAA ENST00000306376 10
ETV5_F_IC CCCTTCCCTCCTCAGCCAGGAGTTC ENST00000306376 8
ETV5_R_NGSP TGGCTGCTGGAGAAATAACCCCCTCT ENST00000306376 9
Table W2. Oligonucleotide Primers Used for RT-PCR.
Primer Oligonucleotide Sequence (5′→3′) Ensembl Transcript Exon
C15orf21_S TCTTTTGGTTGGTGATTTTGATGA ENST00000409454 1
SLC45A3_S GGAACCAGCCTGCACGC ENST00000367145 1
UBTF_S TTGACCCCGGGTTGCC ENST00000393606 2
TMPRSS2 TAGGCGCGAGCTAAGCAGGAG ENST00000332149 1
OR51E2_S ACCACCACCAGGAATTGGC
EST14_S GAAGAGAAGAGAATTCACAGAGTGAAAA
HERVK17_S TTTCCACACTCTCATTCCGGA
ETV1_AS1 TCGTTACAATTTCTCCCACGCT ENST00000430479 4
ETV1_AS2 GCTTAAAGCCTTGTGGTGGG ENST00000430479 9
ETV4_AS GGAGTAAAGGCACTGCTCGC ENST00000319349 6
Table W3. BAC Probes Used to Assess Genomic Rearrangements of ETS Transcription Factors
and Novel 5′ Fusion Partners.
Gene Symbol 5′ Probe (Red) 3′ Probe (Green)
ETV1 RP11-643C13 RP11-790J2
ETV4 RP11-436J4 RP11-831F13
OR51E2 CTC-775N13 NA
Chr14 (q13.3-21.1) RP11-945C4 NA
RP11-666J24
NA indicates not applicable.
Figure W1. RT-PCR screening of gene fusions involving known 5′ fusion partners. Detection of TMPRSS2-ETV1 and SLC45A3-ETV4 fusion
transcripts in PCas P500T and P236T, respectively (A). RT-PCR validation of 5′RACE findings of gene fusions involving known 5′ partners (B).
Figure W2. Expression of UBTF and OR51E2 in different tumor types. The plots representing UBTF (a) and OR51E2 expression (b), respec-
tively, were obtained from the publicly available GeneSapiens database [1]. The blue box represents PCas.
